Forecasting The Future: 6 Analyst Projections For Progyny
Analysts' ratings for Progyny (NASDAQ:PGNY) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 4 | 2 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 2 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $28.83, a high estimate of $32.00, and a low estimate of $26.00. Observing a 10.88% increase, the current average has risen from the previous average price target of $26.00.
Interpreting Analyst Ratings: A Closer Look
The standing of Progyny among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Constantine Davides | Citizens | Announces | Market Outperform | $30.00 | - |
| Scott Schoenhaus | Keybanc | Raises | Overweight | $32.00 | $30.00 |
| Glen Santangelo | Barclays | Announces | Overweight | $29.00 | - |
| Richard Close | Canaccord Genuity | Raises | Hold | $26.00 | $23.00 |
| Scott Schoenhaus | Keybanc | Announces | Overweight | $30.00 | - |
| Lisa Gill | JP Morgan | Raises | Neutral | $26.00 | $25.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Progyny. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Progyny compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Progyny's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Progyny's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Progyny analyst ratings.
All You Need to Know About Progyny
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
Financial Milestones: Progyny's Journey
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Progyny's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 9.32%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Progyny's net margin is impressive, surpassing industry averages. With a net margin of 4.42%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.58%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Progyny's ROA excels beyond industry benchmarks, reaching 1.78%. This signifies efficient management of assets and strong financial health.
Debt Management: Progyny's debt-to-equity ratio is below the industry average. With a ratio of 0.04, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
The Basics of Analyst Ratings
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.